Knowing a tumor’s genetic fingerprint can aid in the diagnosis and prognosis of cancer and inform treatment decisions. SearchLight DNA is an extensively validated, next-generation diagnostic test that identifies important mutations in 120 relevant cancer genes. The most informative canine cancer genetic test available, it incorporates all high-quality diagnostic, prognostic, and predictive biomarkers known from canine and human cancer studies into a proprietary knowledge database.
As a “pan-cancer” precision diagnostic, prognostic, and therapeutic indicator, SearchLight DNA uses a targeted Next-Generation Sequencing (NGS) gene panel to identify point mutations, copy number mutations, and internal tandem duplications in 120 known cancer genes, as well as the chemo-sensitivity gene MDR1. It is appropriate for fine-needle aspirates (FNA), formalin-fixed, paraffin-embedded (FFPE) tissue, or fresh frozen tumor samples.
By finding mutations in the DNA of your patient’s cancer cells, Vidium’s SearchLight DNA can help guide your veterinary team in understanding a cancer’s origin, its behavior, and the optimal approach to its treatment.
Many cancers are recognizable to the trained pathologists and oncologists who diagnose and treat them.
But not all cancers. Sometimes the mutations in a cancer can guide diagnosis, which is a key part of understanding what that tumor will do in the body. Some mutations only occur in specific cancer types or sub-types and so they can aid the veterinary team in identifying the cancer types.
Many mutations have been associated with a better or worse prognosis.
Thinking about the future and what comes next may be the scariest aspect of cancer. Knowing as much as we can about a cancer’s potential behavior is critically important for guiding pet families and veterinarians as they work together to generate the very best plan for that particular cancer in that particular patient and that specific family.
The whole point of understanding cancer is understanding how to stop it.
In human oncology, hundreds of safe and effective “precision therapies” exist that are directed against a cancer’s specific mutations. Fewer precision therapies exist in veterinary medicine, but as we better understand therapeutic targets in pet cancers, we believe that these therapies will become increasingly available. In some cases, we can use human drugs that are available today.
At Vidium, we partner with your pathologists to gain as much information about your patient’s tumor as possible.
Our scientists extract the DNA from your patient’s tumor sample, check it for quality and quantity, sequence the DNA in our state-of-the-art Next-Generation Sequencing (NGS) laboratory, and then analyze (each individual cancer genome) to identify its unique mutations.
We then use our proprietary biomarker database, Vidium Insight, to bring the very latest information on mutation-based diagnostic, prognostic, and treatment guidance to each case.
By using the latest in genomic science, we can learn more about what is driving a tumor and provide valuable, clinically applicable information not available by traditional diagnostic tests.
Pet with suspected cancer visits the veterinarian.
The veterinary team performs a biopsy to collect a sample of the tumor. The sample is sent to Vidium or is sent to a pathologist and then sent to Vidium.
Vidium Animal Health
Vidium performs tumor DNA sequencing and analysis with SearchLight DNA, annotating the tumor mutations with biomarker data from its knowledge database.
Vidium provides a detailed report to the veterinary team with information about the tumor’s mutations and their associations with diagnosis, prognosis, and treatment.